{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["128(8)"],"submitter":["Cuoco S"],"funding":["Università degli Studi di Salerno"],"pubmed_abstract":["<h4>Background</h4>The evidence about the language performance profile of multiple system atrophy (MSA) is limited, but its definition may lead to a more comprehensive characterization of the disorder and contribute to clarify the involvement of the basal ganglia in language abilities.<h4>Objective</h4>The objectives of the study were: (1) to evaluate the reliability of the Screening for Aphasia in NeuroDegeneration (SAND) in MSA patients; (2) compare the linguistic profiles among MSA and Parkinson's disease (PD) patients and healthy controls (HC), and (3) assess relationships between language impairment and cognitive status and MSA motor subtypes.<h4>Methods and results</h4>Forty patients with a diagnosis of MSA, 22 HC and 17 patients with PD were enrolled in the present study. By excluding the writing task that showed a poor acceptability, we showed that the MSA-tailored SAND Global Score is an acceptable, consistent and reliable tool to screen language disturbances in MSA. MSA patients performed worse than HC, but not than PD, in MSA-tailored SAND Global Score, repetition, reading and semantic association tasks. We did not find significant differences between MSA phenotypes. MSA patients with mild cognitive impairment-multiple domain presented worse language performances as compared to MSA patients with normal cognition and mild cognitive impairment-single domain.<h4>Conclusion</h4>The MSA-tailored SAND Global Score is a consistent and reliable tool to screen language disturbances in MSA. Language disturbances characterize MSA patients irrespective of disease phenotype, and parallel the decline of global cognitive functions."],"journal":["Journal of neural transmission (Vienna, Austria : 1996)"],"pagination":["1195-1203"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8322009"],"repository":["biostudies-literature"],"pubmed_title":["The language profile in multiple system atrophy: an exploratory study."],"pmcid":["PMC8322009"],"pubmed_authors":["Cappa S","Barone P","Picillo M","Erro R","Carotenuto I","Catricala E","Cuoco S","Pellecchia MT"],"additional_accession":[]},"is_claimable":false,"name":"The language profile in multiple system atrophy: an exploratory study.","description":"<h4>Background</h4>The evidence about the language performance profile of multiple system atrophy (MSA) is limited, but its definition may lead to a more comprehensive characterization of the disorder and contribute to clarify the involvement of the basal ganglia in language abilities.<h4>Objective</h4>The objectives of the study were: (1) to evaluate the reliability of the Screening for Aphasia in NeuroDegeneration (SAND) in MSA patients; (2) compare the linguistic profiles among MSA and Parkinson's disease (PD) patients and healthy controls (HC), and (3) assess relationships between language impairment and cognitive status and MSA motor subtypes.<h4>Methods and results</h4>Forty patients with a diagnosis of MSA, 22 HC and 17 patients with PD were enrolled in the present study. By excluding the writing task that showed a poor acceptability, we showed that the MSA-tailored SAND Global Score is an acceptable, consistent and reliable tool to screen language disturbances in MSA. MSA patients performed worse than HC, but not than PD, in MSA-tailored SAND Global Score, repetition, reading and semantic association tasks. We did not find significant differences between MSA phenotypes. MSA patients with mild cognitive impairment-multiple domain presented worse language performances as compared to MSA patients with normal cognition and mild cognitive impairment-single domain.<h4>Conclusion</h4>The MSA-tailored SAND Global Score is a consistent and reliable tool to screen language disturbances in MSA. Language disturbances characterize MSA patients irrespective of disease phenotype, and parallel the decline of global cognitive functions.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-19T20:40:31.266Z","creation":"2022-02-11T08:38:46.709Z"},"accession":"S-EPMC8322009","cross_references":{"pubmed":["34216238"],"doi":["10.1007/s00702-021-02372-6"]}}